Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Ravi Limaye gives an overview of the biosimilar industry and projects for 2020.

Outlook for Biosimilars in 2020

Alan Sheppard, Principal, Global Generics at IMS Health and CPhI expert panel member, discusses generic medicine opportunities in the 2016 CPhI Annual Industry Report.

Generic Medicines Provide Growth Opportunities

Three-dimensional (3D) printing, which is a type of additive manufacturing (AM), enables fabrication of specialty drugs and medical devices, said Emil Ciurczak, Doramaxx Consulting and CPhI expert panel member, in the 2016 CPhI Annual Industry Report.

A Vision for 3D Printing in Pharma Manufacturing

Containing costs and improving compliance will be crucial to ensuring the growth of generic pharmaceuticals in the future, says Dilip Shah, CEO of Vision Consulting Group, in CPhI’s 2016 Annual Report, which will be formally issued at CPhI 2016 in Barcelona.

Keeping Generics Relevant: a Wish List from Dilip Shah

The agency approves Amjevita (adalimumab-atto) for the treatment of inflammatory diseases.

FDA Approves Humira Biosimilar

PCI will be participating in two Speakers Corner slots at the ICSE Exhibitor Showcase.

PCI to Share Expertise in Serialization and Handling of Potent Drugs at CPhI

West will showcase several drug-delivery systems and packaging component technologies such as its NovaPure plungers and SmartDose technology platform.

West Features Injectable Packaging and Drug-Delivery Innovations at CPhI 2016

The agency published the guidance to help generic-drug facilities comply with the GDUFA self-identification requirement.

FDA Releases Guidance on GDUFA Self-Identification

R-Pharm facility in Yaroslavl, Russia, is designed to produce biological drugs with GE Healthcare's FlexFactory manufacturing platform.

Flexible Biomanufacturing Facility in Russia Built to Meet Local Demand

Aptar Stelmi will present PremiumCoat, an alternative coated stopper for sensitive drugs, at CPhI 2016.